200 related articles for article (PubMed ID: 17563907)
1. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
Nabili V; Tan JW; Bhuta S; Sercarz JA; Head CS
Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM
Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
4. Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required?
Lee JS; Kwon OJ; Park JJ; Seo JH
J Oral Maxillofac Surg; 2014 May; 72(5):1023-31. PubMed ID: 24480767
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab for the treatment of salivary duct carcinoma.
Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
[TBL] [Abstract][Full Text] [Related]
8. Salivary duct carcinoma: what is already known, and can we improve survival?
Wee DT; Thomas AA; Bradley PJ
J Laryngol Otol; 2012 Jul; 126 Suppl 2():S2-7. PubMed ID: 22495125
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
12. HER-2 profiling and targeting in prostate carcinoma.
Morris MJ; Reuter VE; Kelly WK; Slovin SF; Kenneson K; Verbel D; Osman I; Scher HI
Cancer; 2002 Feb; 94(4):980-6. PubMed ID: 11920466
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
17. Biological therapy of salivary duct carcinoma.
Nashed M; Casasola RJ
J Laryngol Otol; 2009 Feb; 123(2):250-2. PubMed ID: 18405406
[TBL] [Abstract][Full Text] [Related]
18. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Robert N; Leyland-Jones B; Asmar L; Belt R; Ilegbodu D; Loesch D; Raju R; Valentine E; Sayre R; Cobleigh M; Albain K; McCullough C; Fuchs L; Slamon D
J Clin Oncol; 2006 Jun; 24(18):2786-92. PubMed ID: 16782917
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
Kaidar-Person O; Billan S; Kuten A
Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
